Monday January 22nd 2018

Novartis PARADIGMS study shows safety and efficacy of new treatment in pediatric MS patients

Novartis today announced full results from the positive Phase III PARADIGMS study, investigating the safety and efficacy of Gilenya (fingolimod) vs. interferon beta-1a, in children and adolescents (ages 10 to 17) with multiple sclerosis (MS).

View article:

Novartis PARADIGMS study shows safety and efficacy of new treatment in pediatric MS patients

Leave a Comment

More from category

Government Shutdown’s Impact on People with MS
Government Shutdown’s Impact on People with MS

/About-the-Society/News/Government-Shutdown-s-Impact-on-People-with-MS [Read More]

Researchers unravel key molecular mechanism of autoimmune and inflammatory diseases
Researchers unravel key molecular mechanism of autoimmune and inflammatory diseases

An international team of researchers led by prof. Savvas Savvides has unraveled a crucial aspect of the molecular basis [Read More]

Kessler Foundation wins $735,000 grant for training rehabilitation researchers
Kessler Foundation wins $735,000 grant for training rehabilitation researchers

Guang Yue, PhD, director of Human Performance and Engineering Research at Kessler Foundation, has been awarded a [Read More]

6,000-year-old track record for healing leaky gut
6,000-year-old track record for healing leaky gut

When I was traveling in India, I had the privilege of studying Ayurvedic medicine with traditional Master Healers. [Read More]

Study shows high-salt diet causes dementia in mice
Study shows high-salt diet causes dementia in mice

A high-salt diet reduces resting blood flow to the brain and causes dementia in mice, according to a new study by [Read More]